Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Immunology, Harvard Medical School, Boston, MA, USA.
Nat Commun. 2024 Aug 20;15(1):7138. doi: 10.1038/s41467-024-51336-3.
Telomere shortening is a prominent hallmark of aging and is emerging as a characteristic feature of Myelodysplastic Syndromes (MDS) and Idiopathic Pulmonary Fibrosis (IPF). Optimal telomerase activity prevents progressive shortening of telomeres that triggers DNA damage responses. However, the upstream regulation of telomerase holoenzyme components remains poorly defined. Here, we identify RIOK2, a master regulator of human blood cell development, as a critical transcription factor for telomere maintenance. Mechanistically, loss of RIOK2 or its DNA-binding/transactivation properties downregulates mRNA expression of both TRiC and dyskerin complex subunits that impairs telomerase activity, thereby causing telomere shortening. We further show that RIOK2 expression is diminished in aged individuals and IPF patients, and it strongly correlates with shortened telomeres in MDS patient-derived bone marrow cells. Importantly, ectopic expression of RIOK2 alleviates telomere shortening in IPF patient-derived primary lung fibroblasts. Hence, increasing RIOK2 levels prevents telomere shortening, thus offering therapeutic strategies for telomere biology disorders.
端粒缩短是衰老的一个显著标志,也是骨髓增生异常综合征 (MDS) 和特发性肺纤维化 (IPF) 的特征之一。最佳的端粒酶活性可防止端粒的渐进性缩短,从而触发 DNA 损伤反应。然而,端粒酶全酶成分的上游调控仍未得到明确界定。在这里,我们确定了 RIOK2,一种人类血细胞发育的主要调节因子,是端粒维持的关键转录因子。从机制上讲,RIOK2 的缺失或其 DNA 结合/转录激活特性会下调 TRiC 和 dyskerin 复合物亚基的 mRNA 表达,从而削弱端粒酶活性,导致端粒缩短。我们进一步表明,RIOK2 在老年个体和 IPF 患者中的表达减少,并且与 MDS 患者来源的骨髓细胞中端粒缩短强烈相关。重要的是,RIOK2 的异位表达可缓解 IPF 患者来源的原代肺成纤维细胞中端粒缩短。因此,增加 RIOK2 水平可防止端粒缩短,从而为端粒生物学紊乱提供治疗策略。